Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $42.83

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $42.83.

Several research analysts have recently issued reports on the company. Jefferies Financial Group increased their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Wedbush increased their target price on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. HC Wainwright began coverage on Dianthus Therapeutics in a research report on Thursday, May 16th. They set a “buy” rating and a $40.00 price objective for the company. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, Raymond James raised their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the company an “outperform” rating in a research report on Thursday, April 18th.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $26.00 on Monday. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The firm has a market capitalization of $763.10 million, a P/E ratio of -4.46 and a beta of 1.83. The stock has a 50 day moving average price of $23.57 and a 200-day moving average price of $20.56.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $0.48 million. On average, equities analysts forecast that Dianthus Therapeutics will post -2.12 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $25,000. Citigroup Inc. bought a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth $53,000. Acadian Asset Management LLC bought a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth $303,000. Virtu Financial LLC bought a new stake in shares of Dianthus Therapeutics in the 1st quarter worth $390,000. Finally, Laurion Capital Management LP purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter worth $497,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.